Axon loss is an important determinant of weakness in multifocal motor neuropathy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 6, 2006, Pages 743-747

  Van Asseldonk, J T H ^b   Van Den Berg, L H ^b   Kalmijn, S ^a   Van Den Berg Vos, R M ^b   Polman, C H ^c   Wokke, J H J ^b   Franssen, H ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; NEUROPROTECTIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; ELECTROMYOGRAPHY; FEMALE; HISTOLOGY; HUMAN; MALE; MOTOR NEUROPATHY; MULTIVARIATE ANALYSIS; MUSCLE ATROPHY; MUSCLE STRENGTH; NERVE CONDUCTION; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; WEAKNESS; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; MOTOR NEURON DISEASE; MUSCLE WEAKNESS; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AXONS; DEMYELINATING DISEASES; ELECTROMYOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MOTOR NEURON DISEASE; MUSCLE WEAKNESS; MUSCULAR ATROPHY; NEURAL CONDUCTION; NEURODEGENERATIVE DISEASES;

EID: 33646839408     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2005.064816     Document Type: Article

References (53)

1. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8.
2. Donaghy M. Classification and clinical features of motor neurone diseases and motor neuropathies in adults. J Neurol 1999;246:331-3.
3. Leigh PN, Abrahams S, Al Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003;74(suppl 4):iv32-47.
4. Willison HJ, Winer JB. Clinical evaluation and investigation of neuropathy. J Neurol Neurosurg Psychiatry 2003;74(suppl 2):ii3-8.
5. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429-32.
6. Dalakas MC, Stein DP, Otero C, et al. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994;51:861-4.
7. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-52.
8. Sewell WA, Brennan VM, Donaghy M, et al. The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. J Neurol Neurosurg Psychiatry 1997;63:106-9.
9. Ellis CM, Leory S, Payan J, et al. Use of human intravenous immunoglobulin in lower motor neuron syndromes. J Neurol Neurosurg Psychiatry 1999;67:15-19.
10. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
11. Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-53.
12. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002;72:440-8.
13. Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry 2003;74(suppl 2):ii9-14.
14. Azulay JP, Rihet P, Pouget J, et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 1997;62:391-4.
15. Van den Berg-Vos RM, Franssen H, Wokke JH, et al. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875-86.
16. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology 2004;62:666-8.
17. Vucic S, Black KR, Chong PS, et al. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63:1264-9.
18. Van Asseldonk JTH, van den Berg LH, van den Berg-Vos RM, et al. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 2003;126:186-98.
19. Cappellari A, Nobile-Orazio E, Meucci N, et al. Multifocal motor neuropathy: a source of error in the serial evaluation of conduction block. Muscle Nerve 1996;19:666-9.
20. Taylor BV, Wright RA, Harper CM, et al. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-8.
21. Kaji R, Oka N, Tsuji T, et al. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 1993;33:152-8.
22. Taylor BV, Dyck PJ, Engelstad J, et al. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 2004;63:129-37.
23. Van den Berg-Vos RM, Franssen H, Wokke JH, et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 2000;48:919-26.
24. Van den Berg LH, Marrink J, de Jager AE, et al. Anti-GM1 antibodies in patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1992;55:8-11.
25. Van Es HW, van den Berg LH, Franssen H, et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 1997;48:1218-24.
26. Medical Research Council. Aids to the examination of the peripheral nervous system. London: Her Majesty's Stationary Office, 1976.
27. Kimura J. Electrodiagnosis in disease of nerve and muscle: principles and practice, 2nd ed. Philadelphia: FA Davis, 1989.
28. Dumitru D, Diaz CA, King JC. Prevalence of denervation in paraspinal and foot intrinsic musculature. Am J Phys Med Rehabil 2001;80:482-90.
29. Van den Berg LH, Franssen H, Wokke JH. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121:421-8.
30. Franssen H, Wieneke GH. Nerve conduction and temperature: necessary warming time. Muscle Nerve 1994;17:336-44.
31. Franssen H, Vermeulen M, Jennekens FGI. Chronic inflammatory neuropathies. In: Emery A, ed. Diagnostic criteria for neummuscular disorders, 2nd ed. Philadelphia: FA Davis, 1997:53-60.
32. Olney RK, Lewis RA, Putnam TD, et al. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003;27:117-21.
33. Rhee EK, England JD, Sumner AJ. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990;28:146-56.
34. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989;12:435-51.
35. Lange DJ, Trojaborg W, Latov N, et al. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology 1992;42:497-505.
36. Oh SJ, Kim DE, Kuruoglu HR. What is the best diagnostic index of conduction block and temporal dispersion? Muscle Nerve 1994;17:489-93.
37. Goldstein H. Multilevel statistical models, 2nd ed. London: University of London, 1995.
38. Van den Berg-Vos RM, Franssen H, Visser J, et al. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J Neurol 2002;249:330-6.
39. Van den Berg-Vos RM, Visser J, Franssen H, et al. Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain 2003;126:1036-47.
40. Vrancken AF, Franssen H, Wokke JH, et al. Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people. Arch Neurol 2002;59:533-40.
41. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve 1994;17:198-205.
42. Arunachalam R, Osei-Lah A, Mills KR. Transcutaneous cervical roof stimulation in the diagnosis of multifocal motor neuropathy with conduction block. J Neurol Neurosurg Psychiatry 2003;74:1329-31.
43. Nobile-Orazio E, Cappellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002;72:761-6.
44. Santoro M, Uncini A, Corbo M, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 1992;31:385-90.
45. Roberts M, Willison HJ, Vincent A, et al. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol 1995;38:111-18.
46. Sheikh KA, Deerinck TJ, Ellisman MH, et al. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999;122:449-60.
47. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 2003;27:285-96.
48. Kiernan MC, Guglielmi JM, Kaji R, et al. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002;125:664-75.
49. Stys PK, Waxman SG, Ransom BR. Na(+)-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann Neurol 1991;30:375-80.
50. Kapoor R, Davies M, Blaker PA, et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003;53:174-80.
51. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60:1157-62.
52. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000;123:2256-63.
53. Wujek JR, Bjartmar C, Richer E, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002;61:23-32.